Amgen Ventures Backs Ember in $27M Series A; Dividend Strategy Beats AI Trading
AMGN•Amgen Ventures led a strategic Series A funding round boosting Ember LifeSciences to $27 million and supporting full commercial launch of its Ember Cube 2 cold chain platform. Meanwhile, dividend-focused investing in blue-chip biotech stocks like Amgen outperformed AI-driven trading bots, underscoring the stability of dividend returns.
1. Amgen Ventures Leads $27M Funding Round
Amgen Ventures invested in Ember LifeSciences’ Series A round, bringing total funding to $27 million to accelerate full commercial rollout of its modular Ember Cube 2 cold chain solution, which offers real-time monitoring and reusable design for pharmaceutical logistics worldwide.
2. Dividend Investing Surpasses AI Trading Bots
A multi-bot experiment deploying eight leading AI trading bots lost 33% of its $10,000 capital in two weeks, while dividend-focused strategies in blue-chip biotech stocks such as Amgen delivered steady returns, highlighting the resilience of traditional dividend growth approaches.
